UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer

Cancer research (Chicago, Ill.), 2018-04, Vol.78 (8), p.2096-2114

2018

Volltextzugriff (PDF)

Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis

Cancer research (Chicago, Ill.), 2020-06, Vol.80 (11), p.2286-2297

2020

Volltextzugriff (PDF)

Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (7), p.2686-2696

2011

Volltextzugriff (PDF)

The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)

Cancer research (Chicago, Ill.), 2020-03, Vol.80 (5), p.1210-1218

2020

Volltextzugriff (PDF)

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data

Cancer research (Chicago, Ill.), 2015-04, Vol.75 (8), p.1560-1566

2015

Volltextzugriff (PDF)

MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells

Cancer research (Chicago, Ill.), 2008-11, Vol.68 (22), p.9231-9238

2008

Volltextzugriff (PDF)

Abstract 827: Transcriptome-wide association study of endometrial cancer risk

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.827-827

2021

Volltextzugriff (PDF)

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

Cancer research (Chicago, Ill.), 2018-09, Vol.78 (18), p.5419-5430

2018

Volltextzugriff (PDF)

ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7), p.1128-1146

2023

Volltextzugriff (PDF)

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (3), p.505-517

2019

Volltextzugriff (PDF)

Abstract 6231: Multi-omic characterisation of clear cell renal carcinoma reveals endogenous and exogenous processes related to its aetiology

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.6231-6231

2024

Volltextzugriff (PDF)

Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (3), p.467-481

2019

Volltextzugriff (PDF)

Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.4813-4813

2019

Volltextzugriff (PDF)

Abstract 5467: BRCA1 N-terminal-deficient proteins provide PARP inhibitor and platinum resistance

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5467-5467

2015

Volltextzugriff (PDF)

Abstract 506: ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.506-506

2023

Volltextzugriff (PDF)

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor

Cancer research (Chicago, Ill.), 2007-10, Vol.67 (20), p.9887-9893

2007

Volltextzugriff (PDF)

Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10

Cancer research (Chicago, Ill.), 2014-02, Vol.74 (3), p.852-861

2014

Volltextzugriff (PDF)

Abstract 4795: Development of novel, selective, reversible inhibitors equipotent against wild-type and C481S Bruton's tyrosine kinase (BTK)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4795-4795

2016

Volltextzugriff (PDF)

Abstract 82: Molecular characterization of gallbladder cancer

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.82-82

2022

Volltextzugriff (PDF)

Abstract 2079: Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2079-2079

2017

Volltextzugriff (PDF)

Abstract 805: Disruption of the MDM2-p53 interaction synergizes with MEK inhibition to induce cell death and promote tumor regression in p53 wild-type, Ras or Raf-mutant tumor models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.805-805

2014

Volltextzugriff (PDF)

Abstract CT337: Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in triple negative breast cancer (TNBC) at low genetic risk (NCT00647062)

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.CT337-CT337

2014

Volltextzugriff (PDF)

Abstract LB-79: PRC2 loss amplifies Ras-driven transcription and sensitizes cancers to bromodomain inhibitor-based combination therapies

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.LB-79-LB-79

2014

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

KollektionCambridge Journals Online (DEFF)

Zeitschrift / SerieCancer Research

PublikationsformArtikel

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(32)

Sprache

Englisch
(33)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Oncology
(13)
Science & Technology
(13)
Humans
(11)
Female
(8)
Animals
(7)
Mice
(7)
Antineoplastic Agents
(4)
Biological And Medical Sciences
(4)
Medical Sciences
(4)
Ovarian Neoplasms - Genetics
(4)
Pharmacology. Drug Treatments
(4)
Carcinoma, Ovarian Epithelial - Genetics
(3)
Cell Line, Tumor
(3)
Gene Expression Profiling
(3)
Genetic Predisposition To Disease
(3)
Medicin Och Hälsovetenskap
(3)
Mice, Nude
(3)
Polymorphism, Single Nucleotide
(3)
Tumors
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer

Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis

Differentiation of NUT Midline Carcinoma by Epigenomic Reprogramming

The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3)

Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data

MUC4, a multifunctional transmembrane glycoprotein, induces oncogenic transformation of NIH3T3 mouse fibroblast cells

Abstract 827: Transcriptome-wide association study of endometrial cancer risk

A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk

Abstract 6231: Multi-omic characterisation of clear cell renal carcinoma reveals endogenous and exogenous processes related to its aetiology

Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915)

Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus

Abstract 5358: Multi-omics comparative analyses of pulmonary typical carcinoids, atypical carcinoids, and large-cell neuroendocrine carcinoma

Abstract 4813: Comparative activity profiling of tyrosine kinase inhibitors (TKIs) against exon 20 insertions and the wild-type form of epidermal growth factor receptor (EGFR)

Abstract 5467: BRCA1 N-terminal-deficient proteins provide PARP inhibitor and platinum resistance

Abstract 506: ANJ810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor

Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with IL1A and TNFSF10

Abstract 4795: Development of novel, selective, reversible inhibitors equipotent against wild-type and C481S Bruton's tyrosine kinase (BTK)

Abstract 82: Molecular characterization of gallbladder cancer

Abstract 2079: Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR

Abstract 805: Disruption of the MDM2-p53 interaction synergizes with MEK inhibition to induce cell death and promote tumor regression in p53 wild-type, Ras or Raf-mutant tumor models

Abstract CT337: Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O) with carboplatin (C) in triple negative breast cancer (TNBC) at low genetic risk (NCT00647062)

Abstract LB-79: PRC2 loss amplifies Ras-driven transcription and sensitizes cancers to bromodomain inhibitor-based combination therapies

Aktive Filter

Suchergebnisse filtern